X
Poxel taking two shots at NASH as pharma waits on FDA’s OCA verdict
https://pharmaphorum.com/news/poxel-taking-two-shots-at-nash-as/
Intercept
Novartis takes option on NASH drug from Conatus
Swiss pharma takes option on FXR agonist emricasan.
Genfit encounters trial recruitment problem in hunt for NASH patients
Genfit was among a group of NASH companies publishing updates at the International Liver Congress.
Intercept’s liver drug gets green light from NICE
NHS patients to get access to drug in PBC.
Intercept’s Ocaliva approved in EU for liver disease
Potential liver blockbuster gets EU licence.
Gilead to take selonsertib into phase 3 in NASH
But drug flops in two other indications.
EU regulator recommends Intercept’s potential liver blockbuster
Sales forecast to reach $2.6 billion in 2020.
Galectin suffers blow as NASH trial fails
Biotech pins hopes on larger trial.
1 2